WO2003025126A3 - Compositions et procedes destines a l'amorcage de lymphocyte t et immunotherapie - Google Patents

Compositions et procedes destines a l'amorcage de lymphocyte t et immunotherapie Download PDF

Info

Publication number
WO2003025126A3
WO2003025126A3 PCT/US2002/029156 US0229156W WO03025126A3 WO 2003025126 A3 WO2003025126 A3 WO 2003025126A3 US 0229156 W US0229156 W US 0229156W WO 03025126 A3 WO03025126 A3 WO 03025126A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
cells
immunotherapy
gene
Prior art date
Application number
PCT/US2002/029156
Other languages
English (en)
Other versions
WO2003025126A2 (fr
Inventor
Si-Yi Chen
Zhaoyang You
Jenny Hester
Original Assignee
Baylor College Medicine
Si-Yi Chen
Zhaoyang You
Jenny Hester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine, Si-Yi Chen, Zhaoyang You, Jenny Hester filed Critical Baylor College Medicine
Priority to AU2002336522A priority Critical patent/AU2002336522A1/en
Publication of WO2003025126A2 publication Critical patent/WO2003025126A2/fr
Publication of WO2003025126A3 publication Critical patent/WO2003025126A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des compositions et des procédés destinés à amorcer de manière efficace des cellules humaines naïves ex vivo et à identifier des antigènes de classe restreinte au CMH. Le lymphocyte T auxiliaire CD4+ et les lymphocytes T cytotoxiques CD8+ font partie des variétés de lymphocytes T pouvant être amorcés. Les compositions de l'invention contiennent des constructions génétiquement modifiées renfermant un gène destiné à la protéine DC-SIGN et (1) un gène destiné à un antigène modifié ('rétrogène') ou (2) un oligonucléotide soupçonné de coder un antigène de classe restreinte au MHC.
PCT/US2002/029156 2001-09-14 2002-09-13 Compositions et procedes destines a l'amorcage de lymphocyte t et immunotherapie WO2003025126A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002336522A AU2002336522A1 (en) 2001-09-14 2002-09-13 Compositions and methods for t cell priming and immunotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32212001P 2001-09-14 2001-09-14
US60/322,120 2001-09-14

Publications (2)

Publication Number Publication Date
WO2003025126A2 WO2003025126A2 (fr) 2003-03-27
WO2003025126A3 true WO2003025126A3 (fr) 2003-09-04

Family

ID=23253508

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/029156 WO2003025126A2 (fr) 2001-09-14 2002-09-13 Compositions et procedes destines a l'amorcage de lymphocyte t et immunotherapie

Country Status (2)

Country Link
AU (1) AU2002336522A1 (fr)
WO (1) WO2003025126A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073123A1 (en) * 2002-04-30 2006-04-06 Jie Mi Adenovirus vectors for immunotherapy
WO2017075141A1 (fr) * 2015-10-27 2017-05-04 Arizona Board Of Regents On Behalf Of Arizona State University Identification à haut rendement d'antigènes et d'épitopes de reconnaissance des lymphocytes t
EP3402571A4 (fr) 2016-01-15 2019-08-28 The J. David Gladstone Institutes Méthodes de traitement de maladies par la régulation métabolique de la différenciation des lymphocytes t

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962320A (en) * 1993-04-20 1999-10-05 Leland Stanford Junior University Engineered antigen presenting cells and methods for their use
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962320A (en) * 1993-04-20 1999-10-05 Leland Stanford Junior University Engineered antigen presenting cells and methods for their use
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GEIJTENBEEK T.B.H. ET AL.: "Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses", CELL, vol. 100, March 2000 (2000-03-01), pages 575 - 585, XP000929197 *
POHLMANN S. ET AL.: "DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus", J. VIROL., vol. 75, no. 10, May 2001 (2001-05-01), pages 4664 - 4672, XP002963637 *
YOU Z. ET AL.: "A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces protent antitumor T helper and CTL responses", CANCER RESEARCH, vol. 61, no. 1, January 2001 (2001-01-01), pages 197 - 205, XP002963638 *

Also Published As

Publication number Publication date
AU2002336522A1 (en) 2003-04-01
WO2003025126A2 (fr) 2003-03-27

Similar Documents

Publication Publication Date Title
Van Lint et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy
Verbeke et al. Broadening the message: a nanovaccine co-loaded with messenger RNA and α-GalCer induces antitumor immunity through conventional and natural killer T cells
RU2739794C2 (ru) Доставка биомолекул в клетки иммунной системы
ES2791338T3 (es) Célula
Belyakov et al. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells
EP2029165B1 (fr) Vaccin basé sur un lymphocyte b chargé avec le ligand du lymphocyte t nk et antigène
EP1795599A1 (fr) Procédé pour la préparation de cellules T effectrices
Chen et al. Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity
US20120315269A1 (en) Immunoglobulin-like transcript (ilt) receptors as cd8 antagonists
Chung et al. CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo
WO1999042564A3 (fr) Presentation des antigenes aux lymphocytes t au moyen de cellules d'apoptose
EP3255143A2 (fr) Amélioration de l'action stimulante des lymphocytes t de cellules présentant un antigène humain et leur utilisation dans la vaccination
US20170000881A1 (en) Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
WO2011066048A1 (fr) Compositions anti-cancéreuses à base de cellules et leurs procédés de production et d'utilisation
US20080026986A1 (en) Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
Toujas et al. Human monocyte‐derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I‐restricted exogenous peptides
AU2017343893B2 (en) Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
WO2005067460A3 (fr) Vaccins epha2
Weth et al. Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination
WO2003025126A3 (fr) Compositions et procedes destines a l'amorcage de lymphocyte t et immunotherapie
Yip et al. RNA origami functions as a self-adjuvanted nanovaccine platform for cancer immunotherapy
Hellstrom et al. Therapeutic vaccination with tumor cells that engage CD137
US8003093B2 (en) B cell-based vaccine loaded with the ligand of natural killer T cell and antigen
WO2022250811A9 (fr) Nanoparticules pour la programmation de cellules spécifiques d'un antigène et leurs utilisations
Jang et al. Simultaneous expression of allogenic class II MHC and B7. 1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP